Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Rapid test manufacturer Abingdon Health to report full year loss

Published 27/04/2021, 11:55
Updated 27/04/2021, 11:57
© Reuters.

© Reuters.

By Samuel Indyk

Investing.com – Shares in rapid test manufacturer Abingdon Health (LON:ABDX) fell by as much as 30% on Tuesday after the company said they expect to report FY21 performance of a between a £3.3mln loss and breakeven.

The company also anticipates FY21 revenue will be between £11.4mln and £17.0mln.

The AIM-listed company said it continues to make progress on commercialising the AbC-19 rapid test, both in the UK private sector and internationally.

However, the speed of adoption and therefore the receipt of orders is taking longer than the company first anticipated. The board therefore expects FY21 results to be “substantially” below current market expectations.

“Abingdon Health has made significant commercial progress across the COVID-19 and non-COVID-19 markets and the Company expects revenues to more than double this year,” Abingdon Health CEO Chris Yates said in a statement.

“The Company continues to develop a strong pipeline of opportunities for its AbC-19 rapid test. As previously stated, the timing of antibody testing programme roll-outs around the world and future orders is difficult to accurately predict given the range of factors including the evolving regulatory processes, the impact of COVID-19 virus mutations and the rate of vaccination programs.”

DHSC Contract

Abingdon Health also noted that they are still owed outstanding debts from the UK Department of Health and Social Care, in relation to a contract that expired in February 2021. As of 27th April, the company noted they have outstanding invoices with DHSC worth £6.7mln.

At 11:55BST, shares in Abingdon Health were trading lower by 29% at 57.84p per share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.